Drug intelligence / Profile preview

Sperol

Development stage: Preclinical
Lead developer: Aphios
Administration: Oral

Overview

Sperol is a botanical drug product developed by Aphios Corporation, derived from an enhanced extract of saw palmetto (*Serenoa repens*). It is designed to treat benign prostatic hyperplasia (BPH) and male pattern baldness by inhibiting the 5-alpha reductase enzyme. This inhibition prevents the conversion of testosterone into dihydrotestosterone (DHT), a primary driver of prostate enlargement and androgenic alopecia. Sperol utilizes Aphios's patented extraction technology to ensure standardization and potency. While primarily being developed as a pharmaceutical candidate (currently in preclinical stages for BPH), it is also marketed as a dietary supplement (Sperol DS) for promoting healthy prostate function in aging men.

Brand names: SperolSperol DS
Other names: Saw Palmetto extractSerenoa repens extract

Targets

SRD5A (Steroid 5-alpha-reductase)

Beyond the preview

Go deeper on Sperol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sperol.

Explore the full profile